Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRHR | P34981 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6026783 | 1.00 | TRHR (0.46) | TRHR | |
| SCHEMBL29405912 | 1.00 | TRHR (0.46) | TRHR | |
| SCHEMBL27869228 | 1.00 | TRHR (0.46) | TRHR | |
| SCHEMBL3359034 | 0.90 | TRHR (0.44) | TRHR | |
| SCHEMBL28309876 | 0.88 | TRHR (0.41) | TRHR | |
| SCHEMBL11231582 | 0.88 | TRHR (0.41) | TRHR | |
| SCHEMBL716423 | 0.88 | TRHR (0.41) | TRHR | |
| SCHEMBL11034489 | 0.88 | TRHR (0.44) | TRHR | |
| SCHEMBL11309135 | 0.88 | TRHR (0.43) | TRHR | |
| SCHEMBL12667456 | 0.88 | TRHR (0.43) | TRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551535-B2 | Peptide pharmaceuticals for insulin resistance | MEDERIS DIABETES, LLC (US) | 2026-02-17 | — | — | US | claimed |
| US-20240424062-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2024-12-26 | — | — | US | claimed |
| CN-119039384-A | Preparation method of leuprorelin impurity K | 深圳市健元医药科技有限公司 | 2024-11-29 | — | — | CN | claimed |
| CN-118459553-A | GnRH analogue, and preparation method and application thereof | 浙江工业大学 | 2024-08-09 | — | — | CN | claimed |
| CN-118324870-A | Improved peptide drugs for insulin resistance | 梅德瑞斯糖尿病有限责任公司 | 2024-07-12 | — | — | CN | claimed |
| EP-4397374-A2 | IMPROVED PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | Mederis Diabetes, LLC (US) | 2024-07-10 | — | — | EP | claimed |
| CN-117903257-A | Improved peptide drugs for insulin resistance | 梅德瑞斯糖尿病有限责任公司 | 2024-04-19 | — | — | CN | claimed |
| US-11911447-B2 | Peptide pharmaceuticals for insulin resistance | MEDERIS DIABETES LLC (US) | 2024-02-27 | — | — | US | claimed |
| CN-117582516-A | Improved peptide drugs against insulin resistance | 梅德瑞斯糖尿病有限责任公司 | 2024-02-23 | — | — | CN | claimed |
| CN-117343128-A | Synthesis method of buserelin | 成都君诚康正生物科技有限公司 | 2024-01-05 | — | — | CN | claimed |
| CN-116178500-A | Preparation method of leuprorelin related compound | 梯尔希（南京）药物研发有限公司 | 2023-05-30 | — | — | CN | claimed |
| WO-2023030277-A1 | METHOD FOR FULLY LIQUID-PHASE SYNTHESIS OF GRNH NONAPEPTIDE AMIDE ANALOG | 湖南微肽生物医药有限公司 | 2023-03-09 | — | — | WO | claimed |
| WO-2023030278-A1 | FULL-LIQUID-PHASE SYNTHESIS METHOD FOR REELIN DRUG | 湖南三太药业有限公司 | 2023-03-09 | — | — | WO | claimed |
| US-20220362345-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | MEDERIS DIABETES LLC (US) | 2022-11-17 | — | — | US | claimed |
| US-20220348611-A1 | PEPTIDE PHARMACEUTICALS | HERCULES CAPITAL, INC., AS AGENT | 2022-11-03 | — | — | US | claimed |
| CN-110041407-B | Method for synthesizing dessertraline acetate based on Fmoc dipeptide | 南京肽业生物科技有限公司 | 2022-10-28 | — | — | CN | claimed |
| CN-114324669-A | Method for determining L-arginine residue in salmon gonadotropin-releasing hormone analogue by pre-column chiral derivatization | 宁波第二激素厂 | 2022-04-12 | — | — | CN | claimed |
| EP-1991574-B1 | OXYNTOMODULIN DERIVATIVES | MERCK SHARP & DOHME (US) | 2016-10-12 | — | — | EP | claimed |
| US-20050004000-A1 | Oral absorbed drugs | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2005-01-06 | — | — | US | claimed |
| US-3953416-A | Synthetic decapeptide having the activity of the luteinizing hormone releasing hormone and method for manufacturing the same | FOLKERS KARL | 1976-04-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348611-A1 | PEPTIDE PHARMACEUTICALS | PTMS, DNPEP, ANPEP | TRHR 684/4885 |
| US-12551535-B2 | Peptide pharmaceuticals for insulin resistance | IAPP, GLP1R, INSR | TRHR 159/4885 |
| US-20240424062-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | TRHR 199/4885 |
| US-11911447-B2 | Peptide pharmaceuticals for insulin resistance | IAPP, GLP1R, PTMS | TRHR 199/4885 |
| US-20220362345-A1 | PEPTIDE PHARMACEUTICALS FOR INSULIN RESISTANCE | IAPP, GLP1R, PTMS | TRHR 199/4885 |
| US-20050004000-A1 | Oral absorbed drugs | TPMT, CYP2C9, SLCO2B1 | TRHR 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.